Adaptin Bio, Inc. Announces Phase 1 Trial Enrollment for APTN-101

What Happened
Adaptin Bio, Inc. (APTN) announced on August 20, 2026 (8‑K filed August 25, 2026) that enrollment has opened for a Phase 1 clinical trial of its proprietary BRiTE (Brain Bispecific T cell Engager) therapeutic, APTN-101, as a treatment for glioblastoma. The company attached a press release dated August 20, 2026, to the filing.

Key Details

• Event reported under Item 8.01 (Other Events) in an 8‑K filed August 25, 2026.
• Program: APTN-101, a BRiTE (Brain Bispecific T cell Engager) therapeutic candidate.
• Indication: glioblastoma; trial stage: Phase 1 (early clinical stage).
• Press release announcing enrollment is Exhibit 99.1 and was dated August 20, 2026.

Why It Matters
Opening enrollment for a Phase 1 trial is an early but important developmental milestone: Phase 1 studies typically assess safety, tolerability and dosing, and mark the start of human testing. For investors, this progress can be a near-term clinical update cadence driver (patient enrollment, safety readouts) and is relevant to the company’s clinical pipeline outlook. The filing does not include financial results or other operational changes.